Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?

被引:22
|
作者
D'Angelo, Alexa B. [1 ,2 ]
Westmoreland, Drew A. [2 ]
Carneiro, Pedro B. [1 ]
Johnson, Jeremiah [3 ]
Grov, Christian [1 ,2 ]
机构
[1] CUNY, Grad Sch Publ Hlth & Hlth Policy, 55 W 125th St,7th Floor Mailroom, New York, NY 10027 USA
[2] CUNY, Inst Implementat Sci Populat Hlth, New York, NY 10027 USA
[3] Treatment Act Grp, New York, NY USA
关键词
HIV prevention; MSM; qualitative research; PrEP; brand-name drug; GIFTS;
D O I
10.1089/apc.2021.0033
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Safety differences between tenofovir alafenamide/emtricitabine (TAF) and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)-formulated pre-exposure prophylaxis (PrEP) appear to have little clinical significance for most PrEP users. Furthermore, generic TDF-formulated PrEP is projected to decrease the price of PrEP. Thus, efforts to shift PrEP users to TAF-formulated PrEP should be considered in light of their potential to undermine efforts to scale-up PrEP nationally. Data are taken from Together 5,000, a US national cohort study predominantly composed of cisgender gay and bisexual men. In 2019-2020, 5034 participants completed their 24-month assessment, which measured whether participants were switching from TDF (Truvada) to TAF (Descovy) for PrEP, and why. Of those reporting PrEP-use (n = 1009), 277 reported using Descovy for PrEP, and 223 provided a reason for switching to Descovy. A content analysis was used to code participant's reasons for switching. Over half (56%) of participants reported that their doctor recommended switching to Descovy. Without mentioning a provider recommendation, 32% of participants reported that perceived improved safety of Descovy, compared with Truvada, motivated their decision to change their prescription. Other factors cited included the smaller size of the pill and "newness" of Descovy. Further, several participants mentioned negative advertising about Truvada as rationale for switching. Although scientific consensus supports the safety of both TDF/FTC and TAF, our results suggest that current messaging through physicians and other sources have emphasized superior safety of TAF-implying that TDF/FTC may not be safe in the long term. Efforts to shift users onto TAF may undermine public perception of TDF-formulated PrEP.
引用
收藏
页码:327 / 334
页数:8
相关论文
共 50 条
  • [1] Emtricitabine/Tenofovir Alafenamide (Descovy) for HIV
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1500): : 100 - 101
  • [2] No observed bidirectional effect between tenofovir diphosphate concentrations and gender-affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis
    Patel, Nimish
    Morris, Sheldon
    Burke, Leah
    Chow, Karen
    Pacheco, Deedee
    Anderson, Peter
    Stancyzk, Frank
    Blumenthal, Jill
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2360 - 2365
  • [3] Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis
    Bonnichsen, Mark H.
    Tschuchnigg, Mark
    Post, Jeffrey J.
    Bye, William
    [J]. INTERNAL MEDICINE JOURNAL, 2022, 52 (06) : 1099 - 1100
  • [4] Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet
    Wang, Xinzhu
    Nutland, Will
    Brady, Michael
    Green, Ian
    Boffito, Marta
    McClure, Myra
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2019, 30 (08) : 765 - 768
  • [5] Emtricitabine/tenofovir disoproxil fumarate
    不详
    [J]. Drugs in R & D, 2004, 5 (3) : 160 - 161
  • [6] Emtricitabine/tenofovir disoproxil fumarate
    Pozniak, A
    [J]. DRUGS, 2004, 64 (18) : 2083 - 2084
  • [7] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    [J]. HIV MEDICINE, 2020, 21 : 12 - 12
  • [8] Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide
    Blackwell, Christopher W.
    Castillo, Humberto Lopez
    [J]. JNP-JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (06): : 673 - 676
  • [9] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Plosker, Greg L.
    [J]. DRUGS, 2013, 73 (03) : 279 - 291
  • [10] Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis
    Nunes, Rute
    Bogas, Sarah
    Faria, Maria Joao
    Goncalves, Hugo
    Lucio, Marlene
    Viseu, Teresa
    Sarmento, Bruno
    das Neves, Jose
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 334 (334) : 453 - 462